Skip to main content
Fig. 6 | Cancer Imaging

Fig. 6

From: Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?

Fig. 6

Additional sites of disease on WBMRI compared to FDG/PET-CT. 56-year-old female with ER- PR- positive HER-2 negative infiltrating ductal carcinoma with bone and liver metastases. Worsening liver function tests with decreasing haemoglobin and platelet count were noted whilst on Exemestane. Fused PET-CT images (A) and FDG/PET-CT MIP (B) showed no significant pathological activity in the liver. There is pseudocirrhosis, ascites and pleural effusions. High b-value (b900) image (C) and corresponding ADC map (D) of a WBMRI study undertaken four weeks later demonstrated multiple liver metastases measuring up to 20 mm in the posterior right hepatic lobe (yellow arrow) not appreciated on the FDG/PET-CT study

Back to article page